Roche and Foundation Medicine entered a broad strategic collaboration for companion diagnostics and molecular information services. Roche acquired a 56.3% ownership stake in Foundation Medicine for $50/share ($1.03B) and the companies agreed to co-develop next-generation companion diagnostics and molecular profiling products. This licensing/partnership deal gave Roche access to FMI's genomic profiling platform for drug development. Roche later acquired the remaining shares in 2018.